Abstract
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a key mediator of angiogenesis for both physiological and pathological conditions. It is well established that the hypoxic induction of VPF/VEGF is in large part an increase in the stability of its mRNA. A Hu family ubiquitously expressed RNA-binding protein HuR has recently been shown to be important for VPF/VEGF mRNA stabilization. In renal cancer cells, the inactivation of the tumor suppressor protein von Hippel Lindau (VHL) leads to an increase in VPF/VEGF expression. VHL not only inhibits the transcription of VPF/VEGF but also plays a significant role in decreasing its mRNA stability. Here we delineate a possible mechanism by which VHL can control the function of HuR in order to regulate the stability of VPF/VEGF mRNA. The experiments presented here suggest that the association of the elongin-binding domain of VHL with a specific RNA-binding domain of HuR (RRM1) is important for the destabilizing function of VHL on VPF/VEGF mRNA.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bevilacqua A, Ceriani MC, Capaccioli S and Nicolin A . (2003). J. Cell Physiol., 195, 356–372.
Blackshear PJ . (2002). Biochem. Soc. Trans., 30, 945–952.
Brennan CM, Gallouzi IE and Steitz JA . (2000). J. Cell Biol., 151, 1–14.
Chen CY, Gherzi R, Ong SE, Chan EL, Raijmakers R, Pruijn GJ, Stoecklin G, Moroni C, Mann M and Karin M . (2001). Cell, 107, 451–464.
Chen CY, Xu N and Shyu AB . (2002). Mol. Cell Biol., 11, 7268–7278.
Chung J, Yoon S, Datta K, Bachelder RE and Mercurio AM . (2004). Cancer Res., 64, 4711–4716.
Ciais D, Cherradi N, Bailly S, Grenier E, Berra E, Pouyssegur J, Lamarre J and Feige JJ . (2004). Oncogene, 23, 8673–8680.
Claffey KP, Shih SC, Mullen A, Dziennis S, Cusick JL, Abrams KR, Lee SW and Detmar M . (1998). Mol. Biol. Cell, 9, 469–481.
Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ and Maxwell PH . (2000). J. Biol. Chem., 275, 25733–25741.
Datta K, Li J, Bhattacharya R, Gasparian L, Wang E and Mukhopadhyay D . (2004). Cancer Res., 64, 456–462.
Dibbens JA, Miller DL, Damert A, Risau W, Vadas MA and Goodall GJ . (1999). Mol. Biol. Cell, 10, 907–919.
Dvorak HF . (2000). Semin. Perinatol., 24, 75–78.
Dvorak HF . (2002). J. Clin. Oncol., 20, 4368–4380.
Fan XC and Steitz JA . (1998). EMBO J., 17, 3448–3460.
Ferrara N . (2001). Am. J. Physiol. Cell Physiol., 280, C1358–C1366.
Ferrara N . (2002). Nat. Rev. Cancer, 2, 795–803.
Folkman J and Hanahan D . (1991). Princess Takamatsu Symp., 11, 339–347.
Galban S, Martindale JL, Mazan-Mamczarz K, Lopez de Silanes I, Fan J, Wang W, Decker J and Gorospe M . (2003). Mol. Cell. Biol., 23, 7083–7095.
Gallouzi IE, Brennan CM, Stenberg MG, Swanson MS, Eversole A, Maizels N and Steitz JA . (2000). Proc. Natl. Acad. Sci. USA, 97, 3073–3078.
Gherzi R, Lee KY, Briata P, Wegmuller D, Moroni C, Karin M and Chen CY . (2004). Mol. Cell, 14, 571–583.
Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, Grinberg A, Emmert-Buck MR, Westphal H, Klausner RD and Linehan WM . (1997). Proc. Natl. Acad. Sci. USA, 94, 9102–9107.
Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD and Linehan WM . (1996). Proc. Natl. Acad. Sci. USA, 93, 10589–10594.
Goldberg-Cohen I, Furneauxb H and Levy AP . (2002). J. Biol. Chem., 111, 13635–13640.
Iliopoulos O, Levy AP, Jiang C, Kaelin Jr WG and Goldberg MA . (1996). Proc. Natl. Acad. Sci. USA, 93, 10595–10599.
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS and Kaelin Jr WG . (2001). Science, 292, 464–468.
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW and Ratcliffe PJ . (2001). Science, 292, 468–472.
Jiang BH, Agani F, Passaniti A and Semenza GL . (1997). Cancer Res., 57, 5328–5335.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N . (1989). Science, 246, 1306–1309.
Levy AP, Levy NS and Goldberg MA . (1996a). J. Biol. Chem., 111, 25492–25497.
Levy AP, Levy NS and Goldberg MA . (1996b). J. Biol. Chem., 271, 2746–2753.
Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaplin Jr WG and Goldberg MA . (1997). Kidney Int., 51, 575–578.
Lopez de Silanes I, Zhan M, Lai A, Yang X and Gorospe M . (2004). Proc. Natl. Acad. Sci. USA, 101, 2987–2992.
Ma WJ, Cheng S, Campbell C, Wright A and Furneaux H . (1996). J. Biol. Chem., 271, 8144–8151.
Ma WJ, Chung S and Furneaux H . (1997). Nucleic. Acids Res., 25, 3564–3569.
Maher ER and Kaelin Jr WG . (1997). Medicine (Baltimore), 76, 381–391.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ . (1999). Nature, 399, 271–275.
Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S and Sukhatme VP . (1997). Mol. Cell. Biol., 17, 5629–5639.
Myer VE, Fan XC and Steitz JA . (1997). EMBO J., 16, 2130–2139.
Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V and Kaelin WG . (2000). Nat. Cell Biol., 2, 423–427.
Pal S, Datta K, Khosravi-Far R and Mukhopadhyay D . (2001). J. Biol. Chem., 276, 2395–2403.
Papetti M and Herman IM . (2002). Am. J. Physiol. Cell. Physiol., 282, C947–C970.
Peng SS, Chen CY, Xu N and Shyu AB . (1998). EMBO J., 17, 3461–3470.
Pioli PA and Rigby WF . (2001). J. Biol. Chem., 276, 40346–40352.
Raineri I, Wegmueller D, Gross B, Certa U and Moroni C . (2004). Nucleic Acids Res., 32, 1279–1288.
Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JW, Collins D, Majoor-Krakauer D, Bonner T, Mathew C, Rubenstein A, Helperin J, McConkie-Rosell A, Green JS, Trofatter JA, Ponder BA, Eierman L, Bowmer MI, Schimke R, Oostra B, Aronin N, Smith DI, Drabkin H, Waziri MH, Hobbs WJ, Martuza RL, Conneally PM, Hsia YE and Gusella JF . (1988). Nature, 332, 268–269.
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF . (1983). Science, 219, 983–985.
Senger DR, Perruzzi CA, Feder J and Dvorak HF . (1986). Cancer Res., 46, 5629–5632.
Shaw G and Kamen R . (1986). Cell, 46, 659–667.
Shi W and Siemann DW . (2002). Br. J. Cancer, 87, 119–126.
Shim J, Lim H, Yates JR and Karin M . (2002). Mol. Cell, 10, 1331–1344.
Shweiki D, Itin A, Soffer D and Keshet E . (1992). Nature, 359, 843–845.
Stebbins CE, Kaelin Jr WG and Pavletich NP . (1999). Science, 284, 455–461.
Wilusz CJ and Wilusz J . (2004). Trends Genet., 20, 491–497.
Zhang T, Kruys V, Huez G and Gueydan C . (2002). Biochem. Soc. Trans., 30, 952–958.
Acknowledgements
This work was partly supported by NIH Grants CA78383 and HL70567 and also by a grant from the American Cancer Society to DM. SAK was supported by a KO8 award (DK 02825 from NIH).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Datta, K., Mondal, S., Sinha, S. et al. Role of elongin-binding domain of von hippel lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene 24, 7850–7858 (2005). https://doi.org/10.1038/sj.onc.1208912
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208912
Keywords
This article is cited by
-
Multiple functions of HuR in urinary tumors
Journal of Cancer Research and Clinical Oncology (2019)
-
VHL, the story of a tumour suppressor gene
Nature Reviews Cancer (2015)
-
Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma
Tumor Biology (2014)
-
Complex cellular functions of the von Hippel–Lindau tumor suppressor gene: insights from model organisms
Oncogene (2012)
-
HuR expression is a marker of poor prognosis in renal cell carcinoma
Tumor Biology (2011)